Hip Fracture Risk After Treatment with Tramadol or Codeine: An Observational Study

Erica A. Voss (), Saberi Rana Ali, Arun Singh, Peter R. Rijnbeek, Martijn J. Schuemie and Daniel Fife
Additional contact information
Erica A. Voss: Janssen Research & Development LLC
Saberi Rana Ali: Janssen Research & Development LLC
Arun Singh: Janssen Research & Development LLC
Peter R. Rijnbeek: OHDSI Collaborators
Martijn J. Schuemie: Janssen Research & Development LLC
Daniel Fife: Janssen Research & Development LLC

Drug Safety, 2022, vol. 45, issue 7, No 9, 807 pages

Abstract: Abstract Introduction Hip fractures among older people are a major public health issue, which can impact quality of life and increase mortality within the year after they occur. A recent observational study found an increased risk of hip fracture in subjects who were new users of tramadol compared with codeine. These drugs have somewhat different indications. Tramadol is indicated for moderate to severe pain and can be used for an extended period; codeine is indicated for mild to moderate pain and cough suppression. Objective In this observational study, we compared the risk of hip fracture in new users of tramadol or codeine, using multiple databases and analytical methods. Methods Using data from the Clinical Practice Research Datalink and three US claims databases, we compared the risk of hip fracture after exposure to tramadol or codeine in subjects aged 50–89 years. To ensure comparability, large-scale propensity scores were used to adjust for confounding. Results We observed a calibrated hazard ratio of 1.10 (95% calibrated confidence interval 0.99–1.21) in the Clinical Practice Research Datalink database, and a pooled estimate across the US databases yielded a calibrated hazard ratio of 1.06 (95% calibrated confidence interval 0.97–1.16). Conclusions Our results did not demonstrate a statistically significant difference between subjects treated for pain with tramadol compared with codeine for the outcome of hip fracture risk.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01198-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:7:d:10.1007_s40264-022-01198-9

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-022-01198-9

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().